Subscribe
UK-based Ziarco Pharma Ltd. recently announced positive phase 2a results for ZPL-389, a once daily oral histamine H4 receptor antagonist, for the treatment of moderate to severe atopic dermatitis.
Dupilumab demonstrates promising results
Merger to boost eczema offerings
Oatmeal soothes, relieves, and inhibits viruses
Joseph Gorelick, MSN, FNP-C
Brad P. Glick, DO, MPH, FAAD
Hilary Baldwin; Neal Bhatia, MD
Tina Bhutani, MD
June 17-19, 2026
Diego Ruiz Dasilva, MD, FAAD; Brad Glick, DO, MPH. FAAD; Peter Lio, MD
Brittany Weber MD, PhD, FACC, FAHA; Lourdes M. Perez-Chada MD, MMSc
Andrew Alexis, MD, MPH; Leon Kircik, MD
Johann Gudjonsson, MD, PhD; Christopher Bunick, MD, PhD
Andrew F. Alexis, MD, MPH; Chesahna Kindred, MD, MBA, FAAD